Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Keir

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Gut|September 4, 2016
Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UCJean-Frédéric Colombel, Mary E Keir, Alexis Scherl, et al.
Developmental Medicine and Child Neurology|March 27, 2001
Auditory function at 14 years of age of very-low-birthweightN M Davis, L W Doyle, G W Ford, et al.
Lupus|December 1, 2009
Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosusG W Tew, N Rabbee, K Wolslegel, et al.
Journal of Crohn'S & Colitis|June 5, 2024
Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin TherapyFiona B Tamburini, Anupriya Tripathi, Maxwell P Gold, et al.
The Journal of Clinical Investigation|June 17, 2010
PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in miceScott N Mueller, Vijay K Vanguri, Sang-Jun Ha, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 24, 2002
Generation of CD3+CD8low thymocytes in the HIV type 1-infected thymusMary E Keir, Michael G Rosenberg, Johan K Sandberg, et al.
Alimentary Pharmacology & Therapeutics|March 31, 2018
Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel diseaseM T Tang, M E Keir, R Erickson, et al.
Circulation|October 17, 2007
Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heartNir Grabie, Israel Gotsman, Rosa DaCosta, et al.
The Journal of Experimental Medicine|April 12, 2006
Tissue expression of PD-L1 mediates peripheral T cell toleranceMary E Keir, Spencer C Liang, Indira Guleria, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2007
Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct rolesJulia Menke, Julie A Lucas, Geraldine C Zeller, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Gut|September 4, 2016
Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UCJean-Frédéric Colombel, Mary E Keir, Alexis Scherl, et al.
Developmental Medicine and Child Neurology|March 27, 2001
Auditory function at 14 years of age of very-low-birthweightN M Davis, L W Doyle, G W Ford, et al.
Lupus|December 1, 2009
Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosusG W Tew, N Rabbee, K Wolslegel, et al.
Journal of Crohn'S & Colitis|June 5, 2024
Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin TherapyFiona B Tamburini, Anupriya Tripathi, Maxwell P Gold, et al.
The Journal of Clinical Investigation|June 17, 2010
PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in miceScott N Mueller, Vijay K Vanguri, Sang-Jun Ha, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 24, 2002
Generation of CD3+CD8low thymocytes in the HIV type 1-infected thymusMary E Keir, Michael G Rosenberg, Johan K Sandberg, et al.
Alimentary Pharmacology & Therapeutics|March 31, 2018
Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel diseaseM T Tang, M E Keir, R Erickson, et al.
Circulation|October 17, 2007
Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heartNir Grabie, Israel Gotsman, Rosa DaCosta, et al.
The Journal of Experimental Medicine|April 12, 2006
Tissue expression of PD-L1 mediates peripheral T cell toleranceMary E Keir, Spencer C Liang, Indira Guleria, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2007
Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct rolesJulia Menke, Julie A Lucas, Geraldine C Zeller, et al.
Pageof 5